Sanofi‘s (NYSE:SNY) long-acting insulin glargine, Toujeo, met the primary objective of a head-to-head trial comparing it to Novo Nordisk‘s (NYSE:NVO) insulin degludec, Tresiba, the company reported today. The insulin-maker said it plans to report full results from the Bright trial sometime next year. The study’s primary objective was to determine if Toujeo had a similar […]
Novo Nordisk
Facing pressure in diabetes, Novo Nordisk plans next big push – obesity
The world’s largest diabetes drug-maker, Novo Nordisk (NYSE:NVO), is reportedly looking to boost its efforts to treat obesity as the company’s well-established diabetes drugs face competition. At Novo Nordisk’s capital markets day yesterday, CEO Lars Fruergaard Jorgensen told investors that the company wants to rival surgery with their drugs as a solution for obesity. The drug-maker’s […]
Novo Nordisk shares slip on cautious guidance, insulin pricing concerns
Shares in Novo Nordisk (NYSE:NVO) fell slightly today after the insulin-maker met expectations on Wall Street with its third quarter results, but issued cautious sales guidance for 2018. The company’s chief executive expressed concerns that draft legislation to make drug pricing more transparent could potentially hurt the industry, according to Reuters. “If the transparency bills lead to […]
FDA committee backs Novo Nordisk’s once-weekly type II diabetes drug
An FDA advisory committee has voted favorably to approve Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide Type II diabetes drug. Shares in the insulin maker were up 2% in after-hours activity today, trading at $50.13 apiece. While one member of the FDA’s endocrinologic and metabolic drugs advisory committee abstained from voting, the other members voted 16-0 to […]
Here’s how the diabetes industry’s leaders think about patient-centered R&D
Designing devices centered around patients is a goal espoused by nearly all device companies nowadays, as they aim to make products that people want to use and can incorporate into their everyday lives. Underscoring those products is often years of research and some in the industry have begun to think about how a patient’s needs […]
Novo Nordisk wins FDA nod for fast-acting mealtime insulin
Novo Nordisk (NYSE:NVO) said today that the FDA approved its Fiasp insulin aspart injection. The fast-acting mealtime insulin is designed to improve glycemic control for adults with Type I and Type II diabetes. The injection can be taken at the start of a meal or within 20 minutes after starting a meal, Novo Nordisk reported. The […]
China OKs Novo Nordisks’ once-daily Tresiba basal insulin
Novo Nordisk (NYSE:NVO) said today that its once-daily insulin degludec won approval from the China Food and Drug Administration. The insulin-maker’s product is designed to be a once-daily basal insulin with an ultra-long duration of action for people with diabetes. “There are more adults with diabetes in China than anywhere in the world, and we are […]
Nordisk settles DOJ’s Victoza marketing suit for $59m
Novo Nordisk (NYSE:NVO) said yesterday afternoon that it inked a $58.7 million deal with the U.S. Dept. of Justice to settle an investigation into the company’s marketing practices for Victoza – its Type II diabetes drug. The agreement settles eight different lawsuits alleging that the drugmaker misled doctors by dressing salespeople as medical educators, paying physicians […]
FDA clears Nordisk’s Victoza as only Type II diabetes drug to cut cardio risks
The FDA approved a new indication for Novo Nordisk‘s (NYSE:NVO) Victoza liraglutide injection, clearing it as the only Type II diabetes medication indicated to reduce the risk of cardiovascular diseases, like heart attack and stroke. The regulatory watchdog’s decision is based on results from Nordisk’s 9,300-patient Leader trial, which showed that Victoza significantly reduced the […]
Novo Nordisk diabetes drug succeeds in late-stage trial
Shares in Novo Nordisk (NYSE:NVO) rose nearly 5% yesterday afternoon after the insulin-maker said that its once-weekly diabetes drug, semaglutide, succeeded in lowering glucose levels in a late-stage trial. The 40-week trial enrolled 1,200 patients and evaluated two dosages of semaglutide in combination with a standard-of-care-drug. The study compared its drug against Eli Lilly‘s (NYSE:LLY) dulaglutide […]
